☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Secondary Progressive Multiple
Novartis Reports Results of Mayzent (siponimod) in P-III EXPAND Study for Secondary Progressive Multiple Sclerosis
April 21, 2020
Novartis' Mayzent (siponimod) Receives EC's Approval to Treat Patients with Secondary Progressive Multiple Sclerosis with Active D...
January 21, 2020
Load more...
Back to Home
Modal title
×
Modal body text goes here.